CDC Updates Hepatitis B Vaccine Guidelines for Newborns
The Centers for Disease Control and Prevention (CDC) has changed its recommendation regarding the hepatitis B vaccine for newborns. Instead of suggesting that all newborns receive the vaccine, the CDC now advises women who test negative for the virus to speak with their healthcare providers about whether their infants should receive the vaccine within the first 24 hours of life.
This decision came after a vote by the agency’s vaccine advisory committee—newly appointed by Health Secretary Robert F. Kennedy Jr. after dismissing previous members—this month. Acting CDC Director Jim O’Neill approved the recommendation on Tuesday, marking it as the official policy of the agency.
O’Neill stated, “We are restoring the balance of informed consent to parents whose newborns face little risk of contracting hepatitis B.”
The recommendation for a birth dose of the hepatitis B vaccine has been in place since 1991. However, many public health experts voiced concerns over the recent advisory committee’s decision. Following the meeting, a number of doctors and health officials urged O’Neill to disregard the suggestion and keep the original recommendation, but their pleas went unanswered.
Now, if babies do not receive the vaccine at birth, the CDC suggests waiting until they are at least two months old for their first doses. Conversely, it still recommends that infants born to mothers who are hepatitis B positive—or whose status is unknown—should receive the vaccine on their first day of life.
The agency is also considering a secondary recommendation that encourages parents to discuss with health care providers the possibility of testing children for hepatitis B antibodies prior to receiving second doses of the vaccine. Typically, the hepatitis B vaccine is administered in a series of three doses to infants.
This new policy stands out as a significant departure from the general medical consensus. During the advisory committee’s discussions, there were instances of misinformation and selective data, disregarding long-established evidence demonstrating the safety and efficacy of administering the hepatitis B vaccine shortly after birth.
Several public health experts argue that postponing the vaccine could lead to increased hepatitis B infections, potentially resulting in more cases of liver disease or cancer. Statistics show that pediatric cases of acute hepatitis B dropped by 99% from 1990 to 2019 after the CDC recommended the universal birth dose. Notably, the virus can be transmitted from mother to child during delivery, and not all expectant mothers undergo testing.
“Ending the recommendation for newborns makes it more likely that case numbers will rise again, which makes America sicker,” remarked Sen. Bill Cassidy, R-La., a liver doctor who has treated hepatitis B patients. He, along with numerous medical professionals, has publicly asked O’Neill not to adopt the advisory panel’s guidelines.
Despite the new recommendations, pediatricians are expected to continue advocating for the hepatitis B vaccination for newborns. The Department of Health and Human Services has indicated that the changes won’t impact insurance coverage for the vaccinations, and the vaccine will still be available through the Vaccines for Children Program, which provides free vaccinations for uninsured or underinsured children.
The CDC’s decision regarding hepatitis B vaccines is part of a series of recent policy changes that many believe lack scientific backing. This trend has led some public health experts to call into question the reliability of the agency’s recommendations.
Kennedy’s overhaul of the CDC’s vaccine panel earlier this year replaced long-standing members with those skeptical of vaccines. O’Neill, who has a background in investments rather than medicine and previously worked under President George W. Bush, became acting CDC director after Kennedy abruptly fired the previous director, Susan Monarez. Kennedy claimed Monarez was untrustworthy, while Monarez alleged she was dismissed for not endorsing the advisory panel’s recommendations without question.
Moreover, last month, the CDC modified a webpage that previously stated vaccines do not cause autism, now suggesting that studies have not fully eliminated the possibility of a connection. (However, extensive research has consistently found no correlation.)
In October, O’Neill requested vaccine manufacturers to create separate shots for measles, mumps, and rubella, despite lacking evidence to support this change. Additionally, in September, the CDC updated guidelines recommending that pregnant women consider avoiding acetaminophen due to a purported connection to autism, even though much of the scientific evidence does not confirm this link.
In light of these developments, many states are turning to newly formed public health alliances or established medical associations, such as the American Academy of Pediatrics, for guidance instead of relying solely on CDC recommendations. The AAP continues to advocate for the initial dose of the hepatitis B vaccine to be administered within the first 24 hours after birth, followed by additional doses at one to two months and again at six to eighteen months.
